Pregabalin may represent a treatment option for patients with pain related to irritable bowel syndrome (IBS), a pilot study has found.
Researchers from the Mayo Clinic conducted a placebo-controlled trial among 85 patients, ranging between 18 to 70 years of age, who have IBS and reported high levels of abdominal pain. The study lasted for a total of 12 weeks.
The results showed that patients in the pregabalin treated group reported significantly improved pain management compared to these who received placebo. Preliminary data also showed improvement in other IBS symptoms, including bloating and diarrhea.
Pregabalin, marketed under the brand name Lyrica, is FDA-approved to treat fibromyalgia, neuropathic pain, and partial onset seizures.
“Our study does provide preliminary evidence that pregabalin may be an additional treatment option for patients with IBS who have failed other treatment options, but more research is needed,” said Dr. Yuri Saito Loftus, the lead author of the study.
For more information visit MayoClinic.org.